Kamat - Figure 9
American Urological Association
FIG. 9: Today, however, we have clinical risk stratification, which several guidelines have used to recommend 3 categories of NMI bladder cancer. This Figure shows the American Urological Association (AUA)/Society of Urologic Oncology (SUO)'s risk categories: low-risk, intermediate-risk, and high-risk.[7] Any patient who has failed BCG therapy is in the highest risk category of patients according to these guidelines, and this is also true according to the European Association of Urology (EAU)[8] and other guidelines.[9,10]
References
Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer; unabridged version: American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline. Linthicum, MD:American Urological Association; 2016 https://www.auanet.org/documents/education/clinical-guidance/Non-Muscle-Invasive-Bladder-Cancer.pdf Accessed June 17, 2017.
Babjuk M, Böhle A, Burger M, et al.EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 2017;71:447–61 http://dx.doi.org/10.1016/j.eururo.2016.05.041
Spiess PR et al; NCCN Guidelines Version 5.2017 Panel Members Bladder Cancer. NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer Version 5.2017. Fort Washington, PA: National Comprehensive Cancer Network; 2017 https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
National Institute for Health and Care Excellence (NICE). Bladder Cancer: Diagnosis and management. NICE guideline.London,UK: NICE; 2015 https://www.nice.org.uk/guidance/ng2/chapter/1-recommendations
